Monthly Archives: June 2013

EMILIA Trial: T-DM1 in Metastatic Breast Cancer

In February 2013, the FDA approved T-DM1 (ado-trastuzumab emtansine; Kadcyla) for the treatment of patients with HER2-positive metastatic breast cancer. In this segment, panelists discuss the effectiveness of this agent and the pivotal EMILIA trial that led to its approval. Published June 24th 2013 by onclive.com

Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

Dr. Mary Pinder reviews with Nathan Pennell and Howard West promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets. Video by cancergrace.org